Tab. 1 Surrogacy of endpoints with OS depending on the type of therapy.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Surrogate endpoint** | **Chemotherapy-based treatment** | | **Non-chemotherapy-based treatment** | |
| **Number of trials** | **R** | **Number of trials** | **R** |
| PFS | 54 | 0.739 | 55 | 0.519 |
| ORR | 51 | 0.694 | 56 | 0.311 |
| DCR | 51 | 0.659 | 38 | 0.543 |
| 3m PFS | 30 | 0.752 | 33 | 0.468 |
| 6m PFS | 38 | 0.771 | 36 | 0.603 |